Financial Performance - The company's operating revenue for the first half of 2022 was approximately CNY 2.35 billion, representing an increase of 82.32% compared to the same period last year[11]. - The net profit attributable to shareholders of the listed company was approximately CNY 582.99 million, an increase of 27.49% year-on-year[11]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately CNY 462.63 million, reflecting a year-on-year increase of 16.86%[11]. - The basic earnings per share for the period was CNY 0.3198, up 27.51% from the previous year[11]. - The total operating revenue for the first half of 2022 reached CNY 2,349,403,299.73, a significant increase of 82.5% compared to CNY 1,288,596,915.49 in the same period of 2021[74]. - Net profit for the first half of 2022 was CNY 679,971,840.18, representing a 51.1% increase from CNY 449,873,838.47 in the first half of 2021[75]. - The company's operating profit for the first half of 2022 was CNY 789,237,411.61, up from CNY 534,006,824.60 in the previous year, indicating a growth of 47.7%[75]. Assets and Liabilities - The total assets of the company at the end of the reporting period were approximately CNY 14.62 billion, an increase of 26.69% compared to the end of the previous year[11]. - The company's total assets at the end of the first half of 2022 were ¥9,064,045,319.60, reflecting a growth from the previous year[84]. - The company's total liabilities reached CNY 2.98 billion, up from CNY 2.47 billion, reflecting an increase of about 20.5%[72]. - The total equity attributable to shareholders increased to CNY 9.90 billion from CNY 8.34 billion, a growth of approximately 18.7%[72]. Cash Flow - The net cash flow from operating activities was approximately CNY 11.73 million, a significant decrease of 98.42% compared to the previous year[11]. - Cash flow from operating activities generated a net amount of CNY 11,732,435.25, significantly lower than CNY 740,410,409.15 in the previous year[80]. - The total cash and cash equivalents increased by 423.88% to ¥1,292,091,664.07 from ¥246,638,671.00, reflecting improved liquidity[23]. Research and Development - Research and development expenses rose by 19.64% to ¥150,222,277.92 from ¥125,557,702.32, indicating a commitment to innovation[23]. - The company is committed to innovation-driven development, focusing on the R&D of drugs for critical diseases such as tumors and autoimmune diseases[18]. - The company has established a strong R&D platform with multiple laboratories to support the development of blood products, vaccines, and gene-engineered products, ensuring a robust innovation pipeline[19]. Market and Product Development - The company specializes in blood products, vaccines, and biopharmaceuticals, with a diverse range of 11 blood product varieties and 34 specifications[15]. - The company is focused on expanding its market presence and enhancing its product offerings in the biopharmaceutical sector[15]. - The company has launched several vaccines, including seasonal flu and recombinant hepatitis B vaccines[15]. Government Subsidies and Income - The company reported a significant increase in government subsidies, contributing to non-operating income[13]. - Government subsidies are classified into asset-related and income-related subsidies, with the former used for acquiring or constructing long-term assets[191]. Risks and Compliance - The company faces potential risks related to product safety, regulatory compliance, and rising raw material costs, which could impact profit margins[37][38]. - The company emphasizes quality control and has implemented a comprehensive quality assurance system to mitigate industry risks[37]. Shareholder and Equity Information - The company plans not to distribute cash dividends or issue bonus shares for the reporting period[2]. - A total of 4,122,300 restricted shares were unlocked for 111 eligible participants as part of the 2018 restricted stock incentive plan[43]. - The company’s top three shareholders are identified as acting in concert, with a combined holding of approximately 46.09%[65]. Financial Reporting and Compliance - The company's financial report for the first half of 2022 has not been audited[69]. - The financial statements are prepared based on actual transactions and in accordance with the accounting standards issued by the Ministry of Finance[99]. - The company has evaluated its ability to continue as a going concern for the next 12 months and found no significant doubts regarding its ability to continue operations[100].

Financial Performance - The company's operating revenue for 2021 was ¥4,436,200,125.41, a decrease of 11.69% compared to 2020[12]. - The net profit attributable to shareholders for 2021 was ¥1,298,897,164.35, down 19.48% from the previous year[12]. - The net profit after deducting non-recurring gains and losses was ¥1,201,139,755.38, reflecting an 18.71% decrease year-over-year[12]. - The basic earnings per share for 2021 were ¥0.7133, down 19.61% from 2020[12]. - The diluted earnings per share for 2021 were ¥0.7094, a decrease of 19.95% compared to the previous year[12]. - The total operating revenue for 2021 was ¥4,436,200,125.41, a decrease of 11.69% compared to ¥5,023,206,263.40 in 2020[26]. - The operating profit was CNY 1,696,416,227.72, down 21.12% compared to the previous year[20]. - Blood products contributed ¥2,597,779,501.25, accounting for 58.56% of total revenue, with a slight increase of 0.25% year-on-year[26]. - Vaccine products generated ¥1,824,557,525.53, representing 41.13% of total revenue, showing a significant decline of 24.63% from the previous year[26]. Cash Flow and Assets - The net cash flow from operating activities increased by 8.09% to ¥1,432,495,972.60 in 2021[12]. - The cash and cash equivalents at the end of 2021 amounted to ¥692,537,541.18, representing 6.00% of total assets, a decrease of 4.34% from the beginning of the year[46]. - The total assets at the end of 2021 reached ¥11,537,237,136.45, a 14.93% increase from the end of 2020[12]. - The total liabilities amounted to CNY 2.47 billion in 2021, compared to CNY 1.94 billion in 2020, representing an increase of around 27.5%[148]. - The total equity attributable to shareholders increased to CNY 8.34 billion in 2021, up from CNY 7.53 billion in 2020, reflecting a growth of approximately 10.8%[149]. Research and Development - The company has established a strong research and development platform, focusing on blood products, vaccines, and gene-engineered products[26]. - The company aims to develop innovative drugs for critical diseases such as cancer and autoimmune diseases, ensuring safety and accessibility for patients[22]. - The company has 7 monoclonal antibody products in clinical trials, including Adalimumab and Trastuzumab, with several in Phase III trials[20]. - Research and development expenses increased by 18.96% to 253,634,720.97 yuan in 2021 compared to 2020[39]. - The number of R&D personnel rose by 6.37% to 701 in 2021, with the proportion of R&D staff increasing to 23.95% from 22.83%[41]. Market and Product Development - The monoclonal antibody market in China is expected to grow to CNY 194.5 billion by 2025, with a CAGR of 36.5% from 2020 to 2025[20]. - The company is focusing on expanding its vaccine product line and enhancing its competitive edge in the market[19]. - The company is developing several new products, including a recombinant human COVID-19 vaccine and various immunoglobulin products, which are expected to enhance product variety and profit growth[41]. - The company is conducting clinical research on multiple new vaccines, including a four-valent influenza virus vaccine and a rabies vaccine, aimed at increasing market share and competitiveness[41]. Governance and Compliance - The company has established a comprehensive governance structure in compliance with relevant laws and regulations, ensuring strong independence and standardized information disclosure[62]. - The board of directors consists of various specialized committees, including the strategy, nomination, audit, and compensation committees, enhancing operational efficiency[64]. - The company has implemented a transparent performance evaluation and incentive mechanism for its senior management, aiming to attract and retain talent[64]. - The company has a robust investor relations management system to ensure equal treatment of all shareholders, particularly minority shareholders[63]. Risk Management - The company has detailed potential risks that may adversely affect its future development strategy and operational goals in the report[3]. - The company faces risks related to the rising costs of raw plasma and increased competition, which may impact profit margins[58]. - The company is committed to maintaining a high-quality assurance system to mitigate risks associated with product safety and potential adverse reactions[56]. Shareholder and Dividend Policy - The company reported a profit distribution plan to distribute a cash dividend of 2.00 RMB per 10 shares (including tax) to all shareholders, totaling 1,824,366,726 RMB[3]. - The company has a clear and transparent cash dividend policy that aligns with its articles of association and shareholder resolutions[89]. - The company plans to enhance its core competitiveness by accelerating the development of innovative drugs and biosimilars[26]. Environmental and Social Responsibility - The company has implemented measures to reduce carbon emissions and has successfully passed energy management system certification[100]. - There were no environmental penalties or violations reported during the reporting period[100]. - The company actively respects and protects the rights of all stakeholders, including shareholders, employees, and society[64].

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 1,288,596,915.49, a decrease of 7.06% compared to CNY 1,386,540,192.69 in the same period last year[10]. - The net profit attributable to shareholders for the first half of 2021 was CNY 457,282,913.56, down 10.64% from CNY 511,739,953.40 in the previous year[10]. - The net profit after deducting non-recurring gains and losses was CNY 395,891,509.69, a decrease of 14.92% compared to CNY 465,318,823.58 in the same period last year[10]. - The total revenue for the first half of 2021 reached CNY 2,273,695,533.30, an increase from CNY 1,548,264,921.35 in the same period of 2020[80]. - The net profit for the first half of 2021 was CNY 836,403,603.30, compared to CNY 291,088,036.75 in the first half of 2020, representing a growth of approximately 187%[79]. - The total comprehensive income for the first half of 2021 was CNY 449,873,838.47, down from CNY 505,314,841.02 in the same period of 2020[76]. - The total comprehensive income for the period was CNY 457.28 million, reflecting a strong performance despite the challenges faced[88]. Revenue Breakdown - Revenue from blood products accounted for 98.72% of total revenue, with a total of ¥1,272,136,518.25, down 8.28% year-on-year[23]. - Vaccine products saw a significant increase in revenue, reaching ¥9,303,720.74, up 260.67% compared to the previous year[23]. - The company's revenue primarily comes from the production and sale of blood products and vaccines[194]. Cash Flow and Assets - The net cash flow from operating activities increased by 57.05% to CNY 740,915,819.61, compared to CNY 471,757,731.71 in the previous year[10]. - The company's cash and cash equivalents at the end of the reporting period were CNY 1,251,187,912.07, an increase in proportion to total assets from 10.34% to 13.12%[26]. - Cash and cash equivalents as of June 30, 2021, amounted to ¥1,251,187,912.07, an increase from ¥1,038,328,045.65 at the end of 2020[66]. - The cash flow from operating activities for the first half of 2021 was CNY 740,915,819.61, up from CNY 471,757,731.71 in the first half of 2020[81]. Research and Development - Research and development expenses increased by 54.87% to ¥123,222,887.69, indicating a strong focus on innovation[21]. - The company has a strong commitment to R&D in innovative drugs, with ongoing clinical trials for multiple monoclonal antibodies[14]. - The company is focused on developing innovative drugs and biosimilars to address major diseases, enhancing its core competitiveness through strategic partnerships[17]. Market Position and Strategy - The company operates in the blood products, vaccines, and gene engineering sectors, with a diverse range of 34 specifications across 11 blood product varieties[14]. - The company aims to enhance market supply of influenza vaccines and strengthen market expansion efforts in the second half of the year[18]. - The company is the largest influenza vaccine production base in China, with multiple vaccines including quadrivalent influenza virus split vaccine and recombinant hepatitis B vaccine in the market[16]. - The blood products market is expected to grow due to increasing health awareness and aging population, with a shift in demand from human albumin to immunoglobulin and coagulation factor products[16]. Shareholder Information - The total number of shares increased to 1,824,366,726, with 86.09% being unrestricted shares[52]. - The largest shareholder, Chongqing Shengkang Biotechnology Development Co., Ltd., held 15.04% of shares, totaling 274,438,679 shares[59]. - The second largest shareholder, Hong Kong Kekang Co., Ltd., held 13.15% of shares, totaling 239,893,954 shares[59]. Quality and Compliance - The company emphasizes quality management in vaccine production, adhering to the principle of "biological product safety without limits"[17]. - The company emphasizes quality control as a critical measure to mitigate potential risks related to product safety[36]. - The company has not faced any environmental penalties during the reporting period and adheres to relevant environmental protection laws[42]. Financial Position - The total assets at the end of the reporting period were CNY 9,533,510,216.46, a decrease of 5.03% from CNY 10,038,637,131.75 at the end of the previous year[10]. - The net assets attributable to shareholders at the end of the reporting period were CNY 7,493,509,387.83, down 0.47% from CNY 7,528,539,476.95 at the end of the previous year[10]. - The company's total equity at the end of the period was CNY 8.10 billion, showing a stable financial position[87]. Dividends and Shareholder Returns - The company plans not to distribute cash dividends or issue bonus shares for the reporting period[2]. - The company has implemented an employee stock incentive plan, unlocking 5,152,875 restricted shares for 111 individuals as part of its 2018 plan[40]. Legal and Regulatory Matters - The company did not experience any overdue receivables or impairment losses from entrusted financial management[48]. - There were no major litigation or arbitration matters during the reporting period[45]. - The company's semi-annual financial report has not been audited[44].